ScreenerHero
OPTIOptimi Health Corp.
CNQ · CA · Consumer Defensive · Drug Manufacturers - Specialty & Generic · optimihealth.ca
6.400CADMkt Cap: 27.66M $P/E: —

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap27.66M $
Enterprise Value15.10M $
Revenue (TTM)127.93K $
Gross Profit-49.62K $
Net Income (TTM)-2.70M $
Revenue/Share0.0364 USD
Last Price6.400 CAD
Fiscal Year EndSep 2025
MR QuarterJun 2026
Employees—
CountryCA
SectorConsumer Defensive
IndustryDrug Manufacturers - Specialty & Generic
ISINCA68405H1001
Valuation
P/E (Trailing)—
P/E (Forward)-10.42
PEG—
EV/EBITDA-5.14
EV/Revenue118.01
P/S217.40
P/B1.62
EPS (TTM)-2.01
EPS (Forward)-0.64
52W Range
6.3707% of range6.800
52W High6.800 CAD
52W Low6.370 CAD
Profitability
Gross Margin-15.98%
Oper. Margin-957.82%
EBITDA Margin0.00%
Profit Margin-870.75%
ROE-56.49%
ROA-24.40%
Growth
Revenue Growth-28.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.91M $
CapEx (TTM)64.36K $
FCF Margin-890.48%
FCF Yield-4.12%
Net Debt-5.77M $
Net Debt/EBITDA1.96
Balance Sheet
Debt/Equity0.99
Current Ratio1.73
Quick Ratio1.62
Book Value/Sh4.105 CAD
Cash/Share3.043 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateMay 20, 2026
Analyst Consensus
Rating—
Target (Mean)15.00 CAD
Upside (mean)+134.4%
Target Range15.00 CAD – 15.00 CAD
# Analysts1
Ownership
Shares Out.5.73M
Float3.49M
Insiders12.66%
Institutions7.75%
Short Interest
Short Ratio0.1d
Short % Out.0.01%
Shares Short17.55K
Short (prev mo.)1.78K
Technical
SMA 506.570 (-2.6%)
SMA 2008.782 (-27.1%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)3.01K
Avg Vol (10d)5.45K
Technical Indicators
RSI (14)52.3
MACD0.0143
MACD Signal-0.0557
MACD Hist.+0.0700
BB Upper7.231 CAD
BB Middle6.649 CAD
BB Lower6.066 CAD
BB Width17.51%
ATR (14)0.4308 CAD
Vol Ratio (20d)0.33x